Speech by Federal Chancellor Dr. Angela Merkel during her visit to the German Center for Neurodegenerative Diseases (DZNE) on March 15, 2017, in Bonn:

Germany Angela Merkel · Former Chancellor of Germany

16 March 2017 · Visit to the German Center for Neurodegenerative Diseases (DZNE) · German Center for Neurodegenerative Diseases (DZNE), Venusberg, Bonn, Germany

Context
Merkel addressed guests at the inauguration of the new DZNE building in Bonn on March 15, 2017, highlighting Germany's health research achievements.
Main themes
Neurodegenerative diseases research, German Center for Neurodegenerative Diseases (DZNE), health research policy, dementia and Parkinson's disease, German Centers for Health Research, medical progress and innovation, interdisciplinary collaboration, aging and disease burden, federal framework program for health research, basic and applied research balance
Duration
~23 min
73rd percentile
Words
2,796
73rd percentile
Sentences
154
82nd percentile
Readability
47
55th percentile
Grade
11.0
32nd percentile
Syntax
2.83
26th percentile
Vocabulary
2.06
20th percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 60%56%
  • Institutional 16%15%
  • Ceremonial 16%15%
  • Technological 6%5%
  • Geopolitical 2%2%
  • Economic 1%1%
  • Environmental 0%0%
  • Not in focus 6%

154 sentences in 38 paragraphs

Dear Minister Schulze,

dear Professor Nicotera,

dear Ms. Helling-Moegen,

dear Lord Mayor,

dear Annette Schavan,

dear Thomas Rachel,

dear colleagues – I also include the local heroes and all other members in this greeting –, dear Professor Wiestler, the new building of the German Center for Neurodegenerative Diseases is hardly to be overlooked here on the Bonn Venusberg. It can also symbolically be referred to as a lighthouse of research. It radiates the hope that patients suffering from neurodegenerative diseases can be better helped in the future. The spatial interconnection of the three building complexes is striking. This architecture illustrates the collaboration of various scientific disciplines. Ultimately, they all share the goal here of "Research for People – For a Healthy Life!"

Health research is simply the foundation for medical progress that can and should benefit each of us. In hardly any other field of research is the benefit of new findings for the broad majority so clear. However, we also know: the acquisition of knowledge cannot simply be pre-programmed. But it at least requires reliable structures. The response of the federal government to this is our "Framework Program for Health Research." The existence of such a framework program and the identification of institutions for it has a lot to do with Annette Schavan. I would like to express my heartfelt thanks for that. The program has also been continuously pursued.

I myself came from basic research and have always said: You cannot predict anything there; you have to leave room. But I have learned from Annette Schavan that certain structures can rather contribute to success. The questions of structure and freedom are actually constantly at play, and of course here as well.

On the one hand, we have placed a focus on so-called common diseases in the framework program, such as lung and cardiovascular diseases, cancer, or dementia. On the other hand, it is always also about accelerating the application of research results. To this end, we have taken the initiative to pool research capacities. Especially in medical research, the question of when it truly benefits people on a large scale is at least as important as in other fields of research.

In total, there are now six German Centers for Health Research that focus on the most significant common diseases, as the major questions of health research can only or at least much better be answered across disciplines and institutions. Therefore, I believe we can be quite proud of the broad network of clinics, universities, and research institutions in this country. It can already be said: The connection of preclinical and clinical research is of great importance. The six German Centers have succeeded in developing new concepts for diagnoses and therapies in a relatively short time. This has already earned them a high reputation both domestically and abroad.

The German Center for Neurodegenerative Diseases has existed since 2009. At nine locations, over 1,000 employees from various nations are dedicated to research. They overcome institutional and disciplinary boundaries to get to the bottom of things that very few others understand. It is understandable for the vast majority of laypeople how important their research work is for all our health.

Dear Professor Nicotera, dear Ms. Helling-Moegen, what you have set in motion, built, and achieved in just a few years cannot be overestimated in its significance. The German Center for Neurodegenerative Diseases is not yet ten years old but already enjoys an excellent reputation. The quality of the work is reflected in numerous scientific publications, in awards such as the Leibniz Prize, or in the funding from the European Research Council (ERC). This also indicates how much attention is given to the researchers and their field of research.

Not long ago, dementia or Parkinson's disease were still regarded more or less as unavoidable side effects of aging, but fortunately, this perception has changed. Neurodegenerative diseases are now recognized as the challenge they are: painful for those affected and their families, exhausting for the staff in nursing homes, and ultimately burdensome for our entire healthcare system.

Today, around 1.6 million people with dementia live in Germany, and this number is continuing to rise. This is particularly due to more and more people reaching an older age; of course, also thanks to medical progress. As gratifying as a higher life expectancy is, the risk of developing dementia or other neurodegenerative diseases also increases with age. According to estimates by the World Health Organization (WHO), these could even become the second leading cause of death in just over two decades, right after cardiovascular diseases.

What a profound impact a disease can have on those affected as well as on relatives, friends, and acquaintances has been written about, for example, by Inge Jens, who stood by her husband, Walter Jens, who suffered from dementia and whose world of words and clear thinking gradually closed off. In her book, Inge Jens confides to us – I would like to quote her –: "I am convinced he registered exactly how everything slipped away from him, how he stopped being able to write, how reading and finally – in parallel – also speaking became impossible. [...] The loss of a partner who is still alive but has nonetheless forever vanished leaves deep scars." So far, Inge Jens. These words perhaps give us a glimpse of what people with dementia and their families go through. With the progressive loss of memory, life experience, and the ability to communicate with others, the loss of a familiar personality occurs – slowly and irretrievably. This leaves many feeling helpless and desperate.

The diagnosis of dementia is a bitter turning point for both those affected and their relatives. Not much has changed in this regard to this day. Medical research is just beginning to understand the complex causes of dementia diseases. We all naturally hope for progress: starting from basic research for prevention and early diagnosis to clinical research for the development of new and effective treatment methods, and finally to optimal care and support.

Thus, the German Center for Neurodegenerative Diseases is addressing a broad spectrum of tasks. As recognized experts, the employees aim to bring their research results quickly and efficiently into practical application. For this, it is particularly important to be able to involve severely ill patients in the work.

The Bundestag has extensively and very thoroughly discussed this difficult ethical question. The result is a compromise that on the one hand takes into account the well-being of the patient and on the other hand the legitimate desire for medical progress so that other patients can benefit from the research results. This means that under strictly limited conditions, research is permitted even if the affected person cannot consent at the time the research takes place. Nevertheless, great value is placed on the right to self-determination. There must have been a medical consultation at an earlier point in time, after which the willingness to participate in the research had to be clearly expressed.

It is clear: The quality of life of patients generally depends significantly on the quality of medical and nursing care. A large part of the care is in family hands. It is extraordinarily demanding, both physically and mentally. The federal government has done a great deal in recent years to support family caregivers. We have improved the compatibility of care and work and expanded long-term care insurance to an extent that is unprecedented in its twenty-year history. Our first Care Strengthening Act has already brought significant improvements for all approximately 2.7 million people in need of care and their relatives. In particular, we have adjusted the benefits for home care to relieve family members. The second Care Strengthening Act came into effect largely at the beginning of this year. The new rules place even greater emphasis on the individual support needs. There are now five care levels instead of the three tiers that existed previously. We focus on support services to promote and maintain independence as much as possible. This also benefits your work, as we previously had a long-term care insurance system that did not respond adequately to dementia diseases. Therefore, we have taken preventive measures here for all the research results we still expect.

We can rely on the research results of the German Center for Neurodegenerative Diseases for this classification. The care and nursing research is integrated into the work of various disciplines. In close cooperation with the University Hospital Bonn, various professional groups work hand in hand to enable a reasonable comprehensive care. This is nearly unique in Germany in this form.

Care has gained more space through the commitment of research, but also of politics, in recent years. In any case, we in politics and research fundamentally bear the responsibility to address pressing questions for the common good. To clarify what our core themes are, how we approach them, and where we pool our efforts, there is the High-Tech Strategy, which you have already pointed out here. Among the priority areas that have been defined is also healthy living.

Of course, it is not enough to simply be aware of urgent research tasks. To take on tasks also means to make expenditures. Therefore, the federal government has continuously increased its research funds since 2005. The budget of the responsible ministry has more than doubled since then. We have achieved this without compromising our goal of a balanced federal budget. In this context, we have spoken of a growth-oriented consolidation. This means we are using leeway to specifically tap into growth potentials. This means investing in research, investing in development, investing in innovation.

In the field of health, I want us to pursue even more ambitious goals in the coming years. We need to fight cancer even more successfully with an additional billion euros, halt the progression of dementia, and develop effective antibiotics against multi-resistant pathogens.

I also want us to give the health of our children in our society an even higher priority and therefore dedicate a German Center for Health Research to pediatric and adolescent medicine. It must continue to progress.

I want the quality of life of people to be even more at the center of our health and health research policy. Many people in younger years worry about whether they have sufficient health care available. Towards the end of life, one sometimes also fears over-treatment, which leads to more suffering and not to better quality of life. Yes, we must simultaneously minimize over-, under-, and mis-provision. Therefore, it is essential to achieve the optimum everywhere to truly secure quality of life.

That is why I want research and healthcare to jointly answer the question: Which therapy really benefits people? And I want us to comprehensively answer this question based on a large empirical data basis, for example, also through a national quality of life cohort – the Rhineland is already setting a good example here – and make quality of life even more than before the guiding principle for care decisions, always asking about quality of life. I believe that the processing of large data sets – you pointed this out in your speech earlier – will open up previously unrecognized possibilities for us to identify structures with which we can work much more efficiently and much closer to people in the future.

"Germany 2025" – for me, this also means defeating the major scourges of health through more research, a healthcare system focused on the quality of life of people. This is what we want to work on in the coming years.

Research is the foundation for being able to set our own accents in times of great change – for example, with regard to globalization, digitalization, climate change, global population growth, or demographic changes in our own country. I am convinced that much depends on scientific knowledge and its practical application for our future well-being. This is true not only here in our country but worldwide. And I say: Health research, in particular, has a central significance regarding the question of the acceptance of research. We know that there are areas of research where people in Germany are indeed very skeptical.

We see from the example of health research what all comes into play. If you do not have proper equipment, if you do not have proper computers, if you do not have proper mathematical methods, you are indeed at a loss. – Here speaks a former physicist. – It is therefore not only about medicine but always about everything that contributes to quality of life. Only in this way can we truly improve it. It is important to keep saying this. This also holds a special significance for today’s occasion.

As a strong and research-oriented nation, we, together with the other major industrial countries, have a special responsibility for shaping globalization. This particularly concerns health research. The international community has set itself the goal with the 2030 Agenda of giving every woman, every man, and every child in the world the chance for a healthy life. We know that there is still a very long way to go until then. But we in Germany can initiate quite a bit with our partners worldwide to make progress step by step.

Our core concern is – as we made clear during our G7 presidency, and as we are also doing now during our G20 presidency – to minimize global health risks and to prevent the outbreak of dangerous infectious diseases as much as possible. We all still have the Ebola crisis in mind. There were more than 28,600 cases, over 11,300 deaths. These numbers are a poignant reminder to draw lessons from this epidemic. By the way, we were somewhat lucky in the misfortune with Ebola because this disease spread relatively slowly. When we think of the Spanish flu at the beginning of the 20th century, it shows us that we must be prepared very differently under today’s interconnected conditions of globalization.

We have developed recommendations in a process to strengthen the global health architecture. On the one hand, it is about far-reaching prevention, and on the other hand, about a rapid, coordinated international response when there is again an outbreak of dangerous infectious diseases. The G20 health ministers will meet to discuss for the first time, based on a simulation of a fictitious crisis case, how to respond to an epidemic. The heads of state and government will also discuss this. We are also giving increased attention to the issue of antibiotic resistance, because all efforts for better structures are of little use if the necessary therapies are lacking or lose their effectiveness due to resistance.

It is clear – as you can also experience here – that real progress on all these issues can only be achieved through close international cooperation. This is also the reason why we are placing a political focus on global health within the framework of the G20.

We can only approach the political goal of a healthy life through a vibrant research landscape. This requires investments, including in buildings. This new building is a showcase example of cooperation between the federal government and the states – in this case, between the federal government and the state of North Rhine-Westphalia, which is providing the majority of the funding for the construction. I believe that we can achieve good things together here. One of the most modern research buildings in Europe has been created here. With it, the DZNE receives, in both a figurative and literal sense, space for excellent working conditions.

The spirit of innovation in the research of neurodegenerative diseases can be felt in this place. I believe many visitors will also learn a lot about these diseases. I find it very moving that you express the starting point of the loss of abilities here with the handwriting and color design, all the way to what can still be captured at the endpoint.

We need this spirit of innovation. And we need people like you who live this spirit of innovation, who bring your experiences, your ideas, your passion for research into your daily work. Research results cannot be mandated by the state. We can give people money, but we cannot say: "Please come up with something sensible, think of something, be creative." That comes from within. Of course, it must be promoted by good conditions, but that is a value in itself.

I wish you much success, much joy, many great insights at your new place of work, to be honest, also a lot of work – otherwise, research is not fun – and a lot of patience. Because most of the time, it takes a long time, and often you discover something different than you thought. In any case: All the best for your work.